Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (644)	8/22/2000 4:35:36 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1475

Not really certain what they're doing, but I do know that it's fun and at least a tad relevant...... Tuesday August 22, 4:05 pm Eastern Time Press Release SOURCE: Genencor International, Inc. Genencor Obtains Key Rights for Immunology Platform Development - Licenses for i-mune(TM) Mouse Program - PALO ALTO, Calif., Aug. 22 /PRNewswire/ -- Genencor International, Inc. (Nasdaq: GCOR - news) announced today that it has expanded the scope of its licenses from Medarex, Inc. (Nasdaq: MEDX - news) through Medarex's wholly owned subsidiary GenPharm International, Inc. Genencor also announced today that it has licensed a key patent family from Pharming Group NV. Both of these developments are important for advancing the company's i-mune(TM) mouse program. The licenses from Medarex give Genencor the freedom to develop, generate and use mice with transplanted human cells for research and development of commercial non-antibody therapeutic products. The licensed Pharming patents cover the insertion of greater than 50 kb DNA into a mammalian cell or animal, which can be used to introduce human genes into a mouse, an important step in the development of Genencor's i-mune transgenic mouse model. ``This is a very important step in the development of our i-mune mouse model,'' said Dr. Michael V. Arbige, senior vice president of technology for Genencor. ``This model, along with our predictive antigen system, the in vitro i-mune(TM) assay, will further expand our broad reaching immunology platform. Opportunities for this platform are expansive across all of our target markets, but they will certainly play a major role in our developments for the health care market.'' Genencor is currently developing a transgenic mouse model of the human immune system. Current models fail to develop normal immune systems when supplied with allogeneic (mismatched) mouse immune cells or human immune cells. To date, Genencor has developed a novel immuno-deficient mouse model that overcomes the genetic barriers associated with mismatched bone marrow transplantation. Comparable engraftment of human hematopoietic stem cells requires the addition of human factors that are best provided using transgenic methods. Genencor's transgenic mouse model of the human immune system will provide an important tool for the modeling of human infectious diseases and autoimmune disorders, as well as other diseases affecting the immune system. Genencor International is a global leader in the development of genetically based biotechnology products for the health care, agriculture and industrial chemicals markets. Genencor was established in 1982 as a joint venture between Genentech Inc. and Corning Incorporated. Since its founding, Genencor has grown to become a leading biotechnology company, with over $300 million in 1999 revenue, more than 250 biotechnology products in commerce, and over 3,000 owned and licensed patents and applications. Genencor, with more than 1,500 employees worldwide, has principal offices in Palo Alto, California; Rochester, New York; and Leiden, the Netherlands. Except for the historical information contained herein, the matters discussed in this press release may contain forward-looking statements which involve risks and uncertainties, including significant fluctuations in product performance depending on factors such as a dependence on the efforts of third parties, a new and uncertain technology employed by Genencor and its uncertain application to new business ventures, dependence on intellectual property rights, the competitive nature of Genencor's industry and risks of obsolescence of certain technology. Actual results may differ materially from those projected. Forward-looking statements represent the judgment of Genencor as of the date of this release. Genencor disclaims, however, any intent or obligation to update any forward-looking statements. For More Information Investors: Amy Giller, +1-650-846-7500 Media: Angie Blackwell, +1-716-256-5200 SOURCE: Genencor International, Inc.